GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Endoscopy/Remimazolam Improves Sedation Safety During ERCP : GIE | Jun 2026

Remimazolam Improves Sedation Safety During ERCP : GIE | Jun 2026

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated June 1, 2026

Quick Answer

Introduction: Deep sedation is essential for successful endoscopic retrograde cholangiopancreatography (ERCP), a technically complex procedure frequently performed in elderly patients and those with significant comorbidities. Propofol remains the most commonly used sedative agent because of its rapid onset and effectiveness; however, cardiopulmonary adverse events such as hypotension and respiratory instability remain important limitations.


Introduction:

Deep sedation is essential for successful endoscopic retrograde cholangiopancreatography (ERCP), a technically complex procedure frequently performed in elderly patients and those with significant comorbidities. Propofol remains the most commonly used sedative agent because of its rapid onset and effectiveness; however, cardiopulmonary adverse events such as hypotension and respiratory instability remain important limitations.

Problem Statement:

As the complexity and volume of therapeutic endoscopic procedures continue to increase, safer sedation strategies are needed. Remimazolam, an ultra-short-acting benzodiazepine with rapid recovery, predictable metabolism, and the availability of reversal with flumazenil, has emerged as a promising alternative. However, prospective randomized evidence supporting its use specifically during ERCP has been limited.

Summary:

This multicenter randomized controlled trial compared remimazolam with propofol for deep sedation during ERCP. The study demonstrated that remimazolam provided effective procedural sedation while maintaining procedural success and high operator satisfaction. Importantly, remimazolam was associated with a lower incidence of cardiopulmonary adverse events compared with propofol, highlighting a potential safety advantage in a population often characterized by advanced age and multiple medical comorbidities. Despite its improved safety profile, remimazolam maintained adequate sedation quality and did not compromise procedural performance. These findings are particularly relevant for advanced therapeutic endoscopy, where prolonged and stable sedation is required while minimizing hemodynamic and respiratory complications. The pharmacologic characteristics of remimazolam, including rapid onset, short duration of action, organ-independent metabolism, and reversibility with flumazenil, further support its suitability for use outside the operating room environment. As one of the largest prospective randomized studies evaluating remimazolam specifically in the ERCP setting, this trial provides important real-world evidence supporting its clinical adoption. Overall, the results suggest that remimazolam may represent a safer alternative to propofol for deep sedation during ERCP, especially in patients at increased risk for sedation-related complications. Future studies should further define optimal dosing strategies, cost-effectiveness, and outcomes in higher-risk patient populations.

Related Q&A

Duodenal Mucosal Resurfacing REMAIN-1 Study: DDW | 2026

Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...

EUS-FNAB for Solid Pancreatic Lesions: GIE | July 2026

Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...

Durable Endoscopic Partial Reversal of Roux-en-Y Gastric Bypass Using Parallel LAMS Septotomy: GIE | July 2026

Introduction: Although Roux-en-Y gastric bypass (RYGB) is an effective bariatric procedure, a small proportion of patients develop severe nutritional complications, refractory dumping syndrome, or other debilitating adverse events requiring reversal. This study describes a novel...

EUS Double Drainage for Malignant Dual Obstruction : Gut | Jul 2026

Introduction: Simultaneous malignant distal biliary obstruction (MDBO) and gastric outlet obstruction (GOO), commonly caused by advanced pancreatic, biliary, or duodenal cancers, presents a major palliative challenge. Conventional endoscopic approaches often require repeated interventions and may...

Endoscopic Mucosal and Submucosal Cutting in benign esophageal stricture: Gut | July 2026

Introduction: Long benign esophageal strictures remain one of the most difficult benign conditions to manage. Although endoscopic dilation and incision techniques provide temporary relief, recurrence is common, often requiring repeated interventions. This study introduces a...

Economic Impact of POEM and ESD: GIE | June 2026

Introduction: Peroral endoscopic myotomy (POEM) and endoscopic submucosal dissection (ESD) have revolutionized the management of esophageal motility disorders and early gastrointestinal neoplasia. Despite their proven clinical benefits, widespread adoption has been limited by concerns regarding...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer